These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35543641)

  • 1. Commentary: Aducanumab-Related ARIA: Paean or Lament?
    Wassef HR; Colletti PM
    Clin Nucl Med; 2022 Aug; 47(8):707-709. PubMed ID: 35543641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Aducanumab-Related ARIA: Paean or Lament?
    Wassef HR; Colletti PM
    Clin Nucl Med; 2023 Feb; 48(2):168-169. PubMed ID: 36607365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
    Høilund-Carlsen PF; Werner TJ; Alavi A; Revheim ME
    Clin Nucl Med; 2022 Jul; 47(7):625-626. PubMed ID: 35452007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Aducanumab-Related ARIA: Paean or Lament?
    Høilund-Carlsen PF; Alavi A; Revheim ME
    Clin Nucl Med; 2023 Jun; 48(6):505-506. PubMed ID: 36724162
    [No Abstract]   [Full Text] [Related]  

  • 5. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
    Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
    JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
    Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
    Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.
    Howe MD; Britton KJ; Joyce HE; Pappas GJ; Faust MA; Dawson BC; Riddle MC; Salloway SP
    J Prev Alzheimers Dis; 2023; 10(4):765-770. PubMed ID: 37874098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease.
    Muralidharan KK; Karumanchi S; Kowalski KG; Burkett P; Chapel S; Rajagovindan R; Nestorov I
    J Clin Pharmacol; 2022 Aug; 62(8):1030-1046. PubMed ID: 35285968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy.
    Agarwal A; Gupta V; Brahmbhatt P; Desai A; Vibhute P; Joseph-Mathurin N; Bathla G
    Radiographics; 2023 Sep; 43(9):e230009. PubMed ID: 37651273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aducanumab: Appropriate Use Recommendations Update.
    Cummings J; Rabinovici GD; Atri A; Aisen P; Apostolova LG; Hendrix S; Sabbagh M; Selkoe D; Weiner M; Salloway S
    J Prev Alzheimers Dis; 2022; 9(2):221-230. PubMed ID: 35542993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why aducanumab is important.
    Cummings J
    Nat Med; 2021 Sep; 27(9):1498. PubMed ID: 34413516
    [No Abstract]   [Full Text] [Related]  

  • 14. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aducanumab reduces Aβ plaques in Alzheimer's disease.
    Vaillancourt DE
    Mov Disord; 2016 Nov; 31(11):1631. PubMed ID: 27739124
    [No Abstract]   [Full Text] [Related]  

  • 16. Aducanumab: look before leaping.
    Perlmutter JS
    Nat Med; 2021 Sep; 27(9):1499. PubMed ID: 34413517
    [No Abstract]   [Full Text] [Related]  

  • 17. Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities.
    Bechten A; Wattjes MP; Purcell DD; Aliaga ES; Daams M; Brashear HR; Arrighi HM; Barkhof F
    J Neuroimaging; 2017 May; 27(3):318-325. PubMed ID: 28102639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aducanumab: Appropriate use recommendations.
    Cummings J; Salloway S
    Alzheimers Dement; 2022 Mar; 18(3):531-533. PubMed ID: 34314093
    [No Abstract]   [Full Text] [Related]  

  • 20. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.